Contact us
Contact a member of the Novartis team for more information.
Image
Image
Cosentyx® (secukinumab): Mechanism of action
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.1
In Ireland Cosentyx is reimbursed for the following indications: adult plaque psoriasis (PsO); psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).
Please refer to the Summary of Product Characteristics (SmPC) for full prescribing information and safety profile.1
Increased levels of IL-17A are found in the affected tissues of patients with axSpA, PsA, PsO and HS1–3
Image
Cosentyx blocks IL-17A, a key proinflammatory cytokine associated with inflammation in PsA and axSpA1,3–12
How does Cosentyx work?
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information and administration, including dosing in special populations, before prescribing.1
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; ERA; enthesitis-related arthritis; HS, hidradenitis suppurativa; IL-17A, interleukin 17A; IL-23, interleukin 23; JIA, juvenile idiopathic arthritis; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; NK, natural killer; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, summary of product characteristics; TNFα, tumour necrosis factor alpha.
References
Cosentyx® (secukinumab) Summary of Product Characteristics. Available at: www.medicines.ie.
Patel DD, et al. Ann Rheum Dis 2013;72(suppl. 2):ii116–ii123.
Lubberts E. Nat Rev Rheumatol 2015;11(7):415–429.
Smith JA, Colbert RA. Arthritis Rheumatol 2014:66(2):231–241.
Cua DJ, et al. Nat Rev Immunol 2010:10(7):479–489.
Baeten D, et al. N Engl J Med 2015:373(26):2534–2548.
Mease PJ, et al. N Eng J Med 2015;373(14):1329–1339.
McInnes IB, et al. Lancet 2015;386(9999):1137–1146.
Mills KHG. Nat Rev Immunol 2023:23(1):38–54.
Raychaudhuri SP, Raychaudhuri SK. Arthritis Res Ther 2017,19(1):51.
Paroli M, et al. Medicina 2022;58:1552.
Deodhar A, et al. Arthritis Rheumatol 2021;73(1):110–120.
IE11480784 | April 2026
